Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Rawrasauruson Aug 17, 2021 11:26am
273 Views
Post# 33716860

RE:RE:RE:W/e

RE:RE:RE:W/e
Been invested since 2017. Used to post here years ago under a different handle but forgot my log in info after this was more or less put on the back burner in my mind. I made a new account because I saw a lot of people posting that didnt understand the biology behind the drugs and were just speaking nonsense and I didn't want to let bs spread. I'm not promoting a financing deal. I don't want more dilution given how many times it's happened in the past. That being said, we are funded through P3 at the moment with a 2 year runway. Depending on how the data gets processed and what our next steps are, another raise is possible, so is a partnership, so is a buyout. It all depends on how the data prints and what our next steps are from there+ the timelines created. At this point, I'm just hoping that if they need to raise more money down the line that it comes after we have gotten a lot of good news and the stock has rebounded heavily. Raising around 1$ a share would be a nightmare for dilution. Ultimately though, I think either this was an anomaly or we'll end up being fine at 75 mg or lower. I'm really not concerned about the long term prospects of this company, but I know many are so I have tried to ease their concerns. Lastly, who is raw? Not sure I paid attention to their posts but I'll go back and give them a read.
<< Previous
Bullboard Posts
Next >>